Abstract:Herpes virus infection is very common and can manifest as primary, latent or recurrent infection. This virus can establish latent infection in almost all animals. During latent infection, the virus remains dormant, and the host does not show any clinical symptoms. After a stress stimulus, the latent virus is reactivated, thus causing recurrent infection. Prophylactic vaccination remains an effective way to prevent herpes virus infection and control the epidemic of its corresponding diseases. However, although the immune system can control the infection after vaccination, it cannot prevent the recurrence of infection and provide comprehensive protection. A therapeutic vaccine could eliminate latent infection or prevent recurrent infection, thus effectively controlling the recurrence of such diseases. Therefore, vaccination is a feasible strategy for the prevention and control of herpes virus in the future. In this article, the research progress on herpes virus HSV and EBV therapeutic vaccines is reviewed, with an aim to expand the horizons for the development of other herpes virus therapeutic vaccines.
刘占, 马宁宁, 郭子仪, 邓梦梦, 史志斌, 陈陆. 疱疹病毒治疗性疫苗研究进展[J]. 中国人兽共患病学报, 2021, 37(2): 133-137.
LIU Zhan, MA Ning-ning, GUO Zi-yi, DENG Meng-meng, SHI Zhi-bin, CHEN Lu. Research progress in a therapeutic vaccine against herpes virus. Chinese Journal of Zoonoses, 2021, 37(2): 133-137.
[1] Stephenson KE.Therapeutic vaccination for HIV: hopes and challenges[J]. Curr Opin HIV AIDS, 2018,13(5):408-415. DOI:10.1097/COH.0000000000000491 [2] Zhao HJ, Han QJ, Wang G, et al.Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8+ effector memory T cells[J]. Gut, 2019,68(11):2032-2043. DOI:10.1136/gutjnl-2017-315588 [3] Hancock G, Hellner K, Dorrell L.Therapeutic HPV vaccines[J]. Best Pract Res Clin Obstet Gynaecol, 2018,47:59-72. DOI:10.1016/j.bpobgyn.2017.09.008 [4] 祁寒松,吴红霞,仇华吉,等.α疱疹病毒的神经传导——轴突上的“穿梭”[J].生物工程学报,2019,35(8):1361-1373. DOI:10.13345/j.cjb.190050 [5] 余秋颖. 潜伏感染期伪狂犬病病毒EPO基因甲基化状态分析[D].郑州:河南农业大学,2014. [6] 向广韬,吴红霞,仇华吉,等.α疱疹病毒潜伏感染研究进展[J].中国预防兽医学报,2018,40(10):965-970. [7] Birkmann A, Zimmermann H.HSV antivirals- current and future treatment options[J]. Curr Opin Virol,2016,18:9-13. DOI:10.1016/j.coviro.2016.01.013 [8] Hensel MT, Marshall JD, Dorwart MR, et al.Prophylactic herpes simplex virus 2 (HSV-2) vaccines adjuvanted with stable emulsion and toll-like receptor 9 agonist induce a robust HSV-2-specific cell-mediated immune response, protect against symptomatic disease, and reduce the latent viral reservoir[J]. J Virol, 2017,91(9):e02257-16. DOI:10.1128/JVI.02257-16 [9] Johnston C, Gottlieb SL, Wald A.Status of vaccine research and development of vaccines for herpes simplex virus[J]. Vaccine,2016,34(26):2948-2952. DOI:10.1016/j.vaccine.2015.12.076 [10] Cohen JI.Vaccine development for Epstein-Barr virus[J]. Adv Exp Med Biol,2018,1045:477-493. DOI:10.1007/978-981-10-7230-7_22 [11] Cohen JI.Vaccination to reduce reactivation of herpes simplex virus type 2[J]. J Infect Dis,2017, 215(6):844-846. DOI:10.1093/infdis/jix006 [12] Bernstein DI, Flechtner JB, McNeil LK, et al. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease[J]. Vaccine,2019,37(26):3443-3450. DOI:10.1016/j.vaccine.2019.05.009 [13] Bernstein DI, Wald A, Warren T, et al.Therapeutic vaccine for genital herpes simplex virus-2 infection: findings from a randomized trial[J]. J Infect Dis,2017,215(6):856-864. DOI:10.1093/infdis/jix004 [14] Lee AZE, Tan LSY, Lim CM.Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer[J]. Oral Oncol,2018,84:61-70. DOI:10.1016/j.oraloncology.2018.07.011 [15] 朱伟, 黎桂仙, 陈洪浪, 等. CSF2A融合基因真核表达载体的构建及其对EBV^+肿瘤细胞增殖和凋亡的影响[J]. 吉林大学学报(医学版), 2016,(3):424-429. DOI:10.13481/j.1671-587x.20160302 [16] Taylor GS, Jia H, Harrington K, et al.A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer[J]. Clin Cancer Res, 2014,20(19):5009-5022. DOI:10.1158/1078-0432.CCR-14-1122-T [17] Ge Y, Zhou Z, Wang X, et al.In vitro evaluation of the therapeutic effectiveness of EBV-LMP2 recombinant adenovirus vaccine in nasopharyngeal carcinoma[J]. Biomed Pharmacother,2020,121:109626. DOI:10. 1016/j.biopha.2019.109626 [18] 刘芳,向丽.组织常驻记忆T细胞的特性和应用[J]. 科学咨询(科技·管理), 2019, 626(3):68-69. [19] Khan AA, Srivastava R, Chentoufi AA, et al.Bolstering the number and function of HSV-1-specific CD8+ effector memory T cells and tissue-resident memory T cells in latently infected trigeminal ganglia reduces recurrent ocular herpes infection and disease[J]. J Immunol,2017,199(1):186-203. DOI:10.4049/jimmunol.1700145 [20] Shin H, Iwasaki A.A vaccine strategy that protects against genital herpes by establishing local memory T cells[J]. Nature, 2012,491(7424):463-467. DOI:10.1038/nature11522 [21] Xu X, Zhang Y, Li Q.Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development[J]. Rev Med Virol,2019,29(4):e2054. DOI:10.1002/rmv.2054 [22] Bernstein DI, Cardin RD, Bravo FJ, et al.Successful application of prime and pull strategy for a therapeutic HSV vaccine[J]. NPJ Vaccines,2019,4:33. DOI:10.1038/s41541-019-0129-1 [23] Srivastava R, Roy S, Coulon PG, et al.Therapeutic mucosal vaccination of herpes simplex virus 2-infected guinea pigs with ribonucleotide reductase 2 (RR2) protein boosts antiviral neutralizing antibodies and local tissue-resident CD4+ and CD8+ TRM cells associated with protection against recurrent genital herpes[J]. J Virol,2019,93(9):e02309-18. DOI:10.1128/JVI.02309-18 [24] McLaughlin LP, Bollard CM, Keller MD. Adoptive T Cell therapy for Epstein-Barr virus complications in patients with primary immunodeficiency disorders[J]. Front Immunol,2018,9:556. DOI:10.3389/fimmu. 2018.00556 [25] Smith C, Lee V, Schuessler A, et al.Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of T cells impact on clinical response[J]. Oncoimmunology, 2017,6(2):e1273311. DOI:10.1080/2162402X.2016.1273311 [26] Chicaybam L, Abdo L, Carneiro M, et al.CAR T cells generated using sleeping beauty transposon vectors and expanded with an EBV-transformed lymphoblastoid cell line display antitumor activity in vitro and in vivo[J]. Hum Gene Ther,2019,30(4):511-522. DOI:10.1089/hum.2018.218 [27] Pender MP, Csurhes PA, Smith C, et al.Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis[J]. JCI Insight,2018,3(22):e124714. DOI:10.1172/jci.insight.124714 [28] Bieling M, Tischer S, Kalinke U, et al.Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: evaluation of novel naturally processed and presented EBV-derived T-cell epitopes[J]. Oncotarget,2017,9(4):4737-4757.DOI:10.18632/oncotarget.23531 [29] Tzannou I, Papadopoulou A, Naik S, et al.Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation[J]. J Clin Oncol, 2017,35(31):3547-3557. DOI:10.1200/JCO.2017.73.0655 [30] Faist B, Schlott F, Stemberger C, et al.Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy[J]. PLoS One,2019,14(9):e0223258. DOI:10.1371/journal.pone.0223258